Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
1. ANX007 shows significant vision loss protection in early-stage GA patients. 2. 0% of ANX007 patients lost vision vs. 17% in sham group. 3. ANX007 has Fast Track and PRIME designations for regulatory support. 4. The data suggests long-term benefits for visual function preservation. 5. Pivotal Phase 3 ARCHER II study data expected in H2 2026.